59 stories
BPC-157 is a synthetic 15-amino-acid fragment derived from a gastric protein. It became one of the most-requested research peptides in the wellness and longevity market on the strength of preclinical data showing accelerated tendon, ligament, and gut tissue repair — most of which sits in rodent or in-vitro studies, not in human trials.
The regulatory picture has tightened. The FDA placed BPC-157 in Category 2 on the 503A bulks list (insufficient information to evaluate), and the PCAC has heard public comment on whether it belongs there at all. Several state medical boards and the DOJ have moved against clinics and compounding pharmacies selling it for off-label injection. The MHRA has issued enforcement notices in the UK.
The clinical evidence base remains thin, and a 2026 STAT and Undark investigation sharpened the point: nearly all of the roughly 200 BPC-157 studies on PubMed list Croatian researcher Predrag Sikiric or a close colleague as an author, the work carries undisclosed patent and commercial conflicts, and only three human studies have been published. Stories here cover new preclinical work, regulatory action, and any movement toward an actual registered human trial.
Health Canada warned Canadians against injecting unauthorized peptides purchased online, citing risks of organ damage and infection from products misleadingly labeled 'For Research Use Only.'
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
Researchers from UNSW examine the booming trend of injectable peptides marketed for skin repair and anti-aging. They highlight the lack of human clinical evidence and note three people were fined for peptide injections that hospitalized two women at an anti-aging festival.
In-depth feature on peptide mania in wellness culture. HHS Secretary RFK Jr. wants to make unapproved wellness peptides more available to the public. The piece distinguishes FDA-regulated peptides from the largely untested 'wellness' peptides embraced by those mistrustful of mainstream medicine.
Combining multiple peptides like GHK-Cu, BPC-157, and TB-500 is becoming a growing trend, especially among GLP-1 medication users dealing with skin laxity from rapid weight loss. Goop feature explores risks and benefits with dermatologist input.
The UK's MHRA is investigating peptide clinics promoting BPC-157, MOTS-C, and Cortexin with unproven claims. Making medicinal claims classifies these products as medicines under UK law.
Physician-journalist Dhruv Khullar traces the peptide movement from CrossFit communities to mainstream wellness, documenting contamination (lead in BPC-157, endotoxins in TB-500), lack of human trials, and RFK Jr.'s attacks on FDA restrictions.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
The MHRA is investigating whether UK peptide clinics are breaking the law by making medicinal claims for unregulated peptides like BPC-157 and Thymosin Alpha. Clinics were found charging £350–£450/month per peptide despite labeling them "research only."
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
Comprehensive look at peptide therapies from approved GLP-1s to unregulated substances like BPC-157 and TB-500. Most evidence comes from animal studies, with benefits "largely unvalidated in human trials."
A physician essays about a patient who stopped her statin despite high coronary calcium yet continues injecting BPC-157 ordered online, highlighting the growing trust gap between consumer-hyped peptides and evidence-backed medications.
A research review characterizes TB-500 and BPC-157 as distinct informational modulators, with TB-500 linked to thymosin beta-4 biology and BPC-157 acting as a localized signaling stabilizer.
The FDA is moving to allow compounding pharmacies to produce 14+ injectable peptides banned in 2023. Health Secretary RFK Jr. publicly backed the reversal, while top FDA leaders reportedly have reservations about politically-driven decisions.
Longevity enthusiasts anticipate FDA loosening restrictions on BPC-157, ipamorelin, and MOTs-C. Industry notes it may take months for compounding pharmacies to ramp up supply after reclassification.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
London Standard investigation exposes consumers self-injecting BPC-157 and CJC-1295 sourced from Discord groups and online sellers, bypassing medical oversight. UK solicitors warn clinics are on 'very shaky ground.'